肾移植非糖尿病患者血浆置换或透析的危险因素

doi:10.3760/cma.j.issn.1007-1245.2024.06.015

摘要/Abstract

摘要：

目的　探讨肾移植非糖尿病患者血浆置换或透析的危险因素。方法　回顾性研究，收集2019年1月至2020年12月在西安交通大学第一附属医院接受肾移植的507例患者临床资料，其中男349例，女158例，年龄15～65岁。根据移植后1年内有无血浆置换或透析，分为有治疗组（49例）和无治疗组（458例）。采用非参数检验、χ²检验/连续校正χ²检验和Fisher确切概率法比较两组一般资料，多因素logistic回归分析血浆置换或透析的独立危险因素。结果　与无治疗组相比，有治疗组术后第8天空腹血糖（FPG）≥7.8 mmol/L与移植肾功能延迟恢复（DGF）患者比例较高，术后第8天胱抑素C（CysC）和肌酐水平较高，肾小球滤过率较低（χ²=5.202、5.030，Z=-4.676、-5.002、-4.937，均P<0.05）。多因素logistic回归分析发现术后第8天FPG≥7.8 mmol/L［OR=1.216，95%置信区间（CI）1.003～1.473，P<0.05］和术后第8天CysC（OR=1.610，95%CI 1.300～1.995，P<0.05）是血浆置换或透析的独立危险因素。结论　术后第8天FPG和CysC两个临床指标可用来评估是否增加肾移植非糖尿病患者血浆置换或透析的风险，以便早期评估、早期防治。

关键词:

肾移植, 糖尿病, 血浆置换, 透析, 危险因素

Abstract:

Objective　To investigate the risk factors of plasmapheresis or dialysis in non-diabetic patients in kidney transplantation (KT). Methods　A retrospective study was conducted to collect the clinical data of 507 patients who received KT in the First Affiliated Hospital of Xi'an Jiaotong University from January 2019 to December 2020, including 349 males and 158 females, aged 15 to 65 years. According to the occurrence of plasmapheresis or dialysis within 1 year after KT, the patients were divided into a treated group (49 cases) and an untreated group (458 cases). The general data of the two groups were compared by non-parametric test, chi-square test, continuity correction chi-square test, or Fisher exact probability method. The independent risk factors of plasmapheresis or dialysis were analyzed by multivariate logistic regression analysis. Results　Compared with those in the untreated group, the treated group had a higher proportion of fasting plasma glucose (FPG) ≥7.8 mmol/L on the 8th day after KT, a higher proportion of delayed graft function (DGF), higher levels of cystatin C (CysC) and creatinine on the 8th day after KT, and a lower glomerular filtration rate (χ²=5.202 and 5.030, Z=-4.676, -5.002, and -4.937; all P<0.05). Multivariate logistic regression analysis found that the ratio of FPG≥7.8 mmol/L on the 8th day after KT [OR=1.216, 95% confidence interval (CI) 1.003-1.473, P<0.05] and CysC on the 8th day after KT (OR=1.610, 95%CI 1.300-1.995, P<0.05) were independent risk factors for plasmapheresis or dialysis. Conclusions　FPG ≥7.8 mmol/L and CysC on the 8th day after KT are the independent risk factors of plasmapheresis or dialysis in non-diabetic patients with KT, so as to facilitate early assessment, prevention, and treatment.

Key words:

Kidney transplantation, Diabetes mellitus, Plasmapheresis, Dialysis, Risk factors

王乐陈颖力张凯璐张银福杜瑞妮高巍.

肾移植非糖尿病患者血浆置换或透析的危险因素 [J]. 国际医药卫生导报, 2024, 30(6): 953-957.

Wang Le, Chen Yingli, Zhang Kailu, Zhang Yinfu, Du Ruini, Gao Wei.

Risk factors for plasmapheresis or dialysis in non-diabetic patients with kidney transplantation [J]. International Medicine and Health Guidance News, 2024, 30(6): 953-957.

参考文献

[1] Goyal VK, Solanki SL, Baj B. Pulmonary hypertension and post-operative outcome in renal transplant: a retrospective analysis of 170 patients[J]. Indian J Anaesth, 2018,62(2):131-135.DOI: 10.4103/ija.IJA_529_17.
[2] Weeda ER, Su Z, Taber DJ,et al. Costs and factors associated with heart failure following kidney transplantation - a single-center retrospective cohort study[J]. Transpl Int,2020,33(4):414-422. DOI: 10.1111/tri.13571.
[3] 中国医药生物技术协会移植技术分会,上海市肾脏移植质控中心专家委员会. 肾移植后期抗体介导排斥反应防治专家共识[J]. 中华医学杂志,2022,102(26):1973-1981. DOI:10.3760/cma.j.cn112137-20220129-00217.
[4] Hussain A, Culliford A, Phagura N,et al. Comparing survival outcomes for kidney transplant recipients with pre-existing diabetes versus those who develop post-transplantation diabetes[J]. Diabet Med,2022,39(2):e14707.DOI: 10.1111/dme.14707.
[5] Lemoine M, Titeca Beauport D, Lobbedez T,et al. Risk factors for early graft failure and death after kidney transplantation in recipients older than 70 years[J]. Kidney Int Rep,2019,4(5):656-666.DOI: 10.1016/j.ekir.2019.01.014.
[6] Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants[J]. Nat Rev Endocrinol,2019 ,15(3):172-188.DOI: 10.1038/s41574-018-0137-7.
[7] González Delgado A, Hernández AF, Marrero D,et al. Inflammation on the waiting list is a risk factor for new-onset prediabetes and post-transplant diabetes mellitus: a prospective study[J]. Nephron, 2023,147(9):560-571.DOI: 10.1159/000531334.
[8] 王莉. 肾移植后1年存活者空腹血糖变化及预后[J]. 中国组织工程研究,2015(24):3924-3928. DOI:10.3969/j.issn.2095-4344.2015.24.028.
[9] Nacak H, Bolignano D, Van Diepen M,et al. Timing of start of dialysis in diabetes mellitus patients: a systematic literature review[J]. Nephrol Dial Transplant, 2016,31(2):306-316. DOI: 10.1093/ndt/gfv431.
[10] 戴天增,黄雪梅,方潇,等. 代谢综合征对移植肾功能延迟恢复及预后的影响[J]. 肾脏病与透析肾移植杂志,2022,31(1):45-51. DOI:10.3969/j.issn.1006-298X.2022.01.008.
[11] 索敬钧,杨青彦,李涛,等. 含西罗莫司的四联免疫抑制剂方案对肾移植术后患者肾功能、T淋巴细胞亚群及预后的影响[J]. 国际医药卫生导报,2022,28(6):752-755. DOI:10.3760/cma.j.issn.1007-1245.2022.06.004.
[12] Tian N, Meng H, Fung WWS,et al. Peritoneal dialysis after failed kidney allograft: comparing patients with and without pd before transplant[J]. PLoS One, 2023,18(7):e0284152.DOI: 10.1371/journal.pone.0284152.
[13] Krogstrup NV, Oltean M, Nieuwenhuijs-Moeke GJ,et al. Remote ischemic conditioning on recipients of deceased renal transplants does not improve early graft function: a multicenter randomized, controlled clinical trial[J]. Am J Transplant, 2017,17(4):1042-1049.DOI: 10.1111/ajt.14075.
[14] Kim B, Kang M, Lee JK,et al. Perioperative blood usage and therapeutic plasma exchange in kidney transplantation during a 16-year period in South Korea[J]. Blood Transfus,2021,19(2):102-112.DOI: 10.2450/2020.0050-20.
[15] Loera JM, Barrett SC, Zhang TS,et al. The impact of diabetes on young transplant recipients: an American perspective[J]. Nephrology (Carlton), 2022,27(5):450-457.DOI: 10.1111/nep.14019.
[16] 陈敏灵,于明香,许明,等. 肾移植术后空腹血糖变化规律及其对预后的影响分析[J]. 中华内分泌代谢杂志,2012,28(1):40-44. DOI:10.3760/cma.j.issn.1000-6699.2012.01.013.
[17] Palermo NE, Gianchandani RY, McDonnell ME,et al. Stress hyperglycemia during surgery and anesthesia: pathogenesis and clinical implications[J]. Curr Diab Rep, 2016,6(3):33. DOI: 10.1007/s11892-016-0721-y.
[18] Zelle DM, Corpeleijn E, Deinum J,et al. Pancreatic β-cell dysfunction and risk of new-onset diabetes after kidney transplantation[J]. Diabetes Care, 2013,36(7):1926-1932.DOI: 10.2337/dc12-1894.
[19] Hermayer KL, Egidi MF, Finch NJ,et al. A randomized controlled trial to evaluate the effect of glycemic control on renal transplantation outcomes[J]. J Clin Endocrinol Metab,2012,97(12):4399-4406.DOI: 10.1210/jc.2012-1979.
[20] Bergrem HA, Valderhaug TG, Hartmann A,et al. Glucose tolerance before and after renal transplantation[J]. Nephrol Dial Transplant, 2010,25(3):985-992.DOI: 10.1093/ndt/gfp566.
[21] Umpierrez G, Cardona S, Pasquel F,et al. Randomized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG trial[J]. Diabetes Care, 2015,38(9):1665-1672.DOI: 10.2337/dc15-0303.
[22] Bang JY, Kim SG, Oh J,et al. Impact of remote ischemic preconditioning conducted in living kidney donors on renal function in donors and recipients following living donor kidney transplantation: a randomized clinical trial[J]. J Clin Med,2019,8(5):713. DOI: 10.3390/jcm8050713.
[23] 丁宁,郑洁,赵慧颖,等. Kt与胱抑素C清除率在高通量血液透析中的相关性及临床应用[J]. 中国血液净化,2021,20(9):586-590. DOI:10.3969/j.issn.1671-4091.2021.09.003.
[24] Mao Q, Zhao N, Wang Y,et al. Association of cystatin C with metabolic syndrome and its prognostic performance in non-st-segment elevation acute coronary syndrome with preserved renal function[J]. Biomed Res Int, 2019,2019:8541402.DOI: 10.1155/2019/8541402.
[25] Yang T, Pei D. Association of cystatin C levels with metabolic syndrome incidence: a nested case-control study with propensity score matching[J]. J Int Med Res, 2021,49(1):300060520986311. DOI: 10.1177/0300060520986311.
[26] 汪博,李亚娟,阳婷婷,等. 胱抑素C对肾移植术后发生肾功能延迟恢复的预测价值[J]. 重庆医学,2022,51(14):2353-2357,2361. DOI:10.3969/j.issn.1671-8348. 2022.14.003.
[27] 余红,张川,乐涛,等. 血清CysC、MCP-1、ACTA水平在评估老年COPD合并呼衰预后的价值分析[J]. 标记免疫分析与临床,2022,29(4):599-603. DOI:10.11748/bjmy.issn.1006-1703.2022.04.013.
[28] Li F, Hu L, Zhao X,et al. The value of cystatin C and urinary and serum neutrophil gelatinase-associated lipocalin during the perioperative period of renal transplantation[J]. Transl Androl Urol, 2019,8(5):432-441.DOI: 10.21037/tau.2019.08.12.
[29] Shan XS, Hu LK, Wang Y,et al. Effect of perioperative dexmedetomidine on delayed graft function following a donation-after-cardiac-death kidney transplant: a randomized clinical trial[J]. JAMA Netw Open, 2022,5(6):e2215217.DOI: 10.1001/jamanetworkopen.2022.15217.
[30] Liu Z, Jin Y, Feng C,et al. Renoprotective effect of intraoperative dexmedetomidine in renal transplantation[J]. Comput Math Methods Med,2022,2022:9275406.DOI: 10.1155/2022/9275406.
[31] Jadlowiec CC, Frasco P, Macdonough E,et al. Association of DGF and early readmissions on outcomes following kidney transplantation[J]. Transpl Int,2022,35:10849.DOI: 10.3389/ti.2022.10849.